Post-chemotherapy C-reactive protein/albumin ratio predicts prognosis in stage II-III colorectal cancer

Table 3 The relationship between the C-reactive protein/albumin ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index and clinicopathological characteristics in II/III patients with colorectal cancer

		Age	Sex		Site		CEA (ng/mL)		TNM
			Female	Male	Colon	Rectum	< 5	≥ 5	II	III
CAR	Low	61.44	145	185	235	95	215	115	165	165
Post-adjuvant chemotherapy	High	62.96	55	160	70	45	40	75	15	100
	P value	0.21	0.8102		0.436		0.0148		0.0026
NLR	Low	62.69	115	110	155	70	150	75	105	120
Post-adjuvant chemotherapy	High	60.95	85	135	150	70	105	115	75	145
	P value	0.11	0.2888		0.9999		0.0882		0.282
PLR	Low	61.61	95	110	145	60	120	85	100	105
Post-adjuvant chemotherapy	High	62.02	105	135	160	80	135	105	80	160
	P value	0.71	0.0054		0.0385		0.1953		0.8268
SII	Low	62.66	160	180	230	110	205	135	160	180
Post-adjuvant chemotherapy	High	59.14	40	65	75	30	150	55	20	85
	P value	0.01	0.6168		0.7954		0.3246		0.0244

CEA: Carcinoembryonic antigen; TNM: Tumor-node-metastasis; CAR: C-reactive protein/albumin ratio; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune-inflammation index.